BioSpace News Archive

ANI Pharmaceuticals, Inc. announced that the Company has re-filed its supplemental new drug application for Cortrophin® Gel with the U.S. Food and Drug Administration.

Arbutus Biopharma Corporation and Vaccitech plc announced that the companies have entered into a clinical trial collaboration agreement to evaluate an innovative therapeutic combination for the treatment of subjects with chronic hepatitis B virus infection who are already receiving standard-of-care nucleoside reverse transcriptase inhibitor therapy.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced positive safety results from its Phase 1 clinical trial of EYP-1901, a potential twice-yearly sustained delivery anti-VEGF treatment targeting wet age-related macular degeneration.

Biomet Holdings, Inc. announced its second quarter earnings conference call will be webcast on Tuesday, August 3, 2021 at 8:30 a.m. ET.

TheraCell Inc., a leading allograft solution company, announced that over 200 of its proprietary Fiber Anchors have been implanted.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the Company’s Biologics License Application for teplizumab for the delay of clinical type 1 diabetes in at-risk individuals.

Allurion Technologies announced today two major milestones with the launch of the transformed Allurion Weight Loss Program and new worldwide brand for the company and its program.

Cybin Inc. today announced that it has entered into an exclusive research and development collaboration agreement (the “ Collaboration Agreement ”) with TMS NeuroHealth Centers Inc., a wholly-owned subsidiary of Greenbrook TMS Inc.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from the first two cohorts of AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).

Over the period of analysis, the global gene delivery technologies market is projected to develop at a healthy growth pace.